Short Interest in Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Rises By ∞

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 75,707 shares, an increase of ∞ from the April 15th total of 0 shares. Based on an average trading volume of 578,100 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Lakewood-Amedex Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd.

Lakewood-Amedex Biotherapeutics Stock Down 23.5%

NASDAQ LABT opened at $1.50 on Friday. Lakewood-Amedex Biotherapeutics has a one year low of $1.41 and a one year high of $9.82.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.